Biocept’s Liquid Biopsy Lung Cancer Target Selector Assay to be featured at World Conference on Lung Cancer

Clinical Data Shows Assay’s Utility in Therapeutic Management of Patients with Non-Small Cell Lung Cancer

SAN DIEGO--()--Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that clinical data from a study conducted with researchers at the University of California, San Diego’s Moores Cancer Center indicate that Biocept’s lung cancer Target Selector™ assay has high concordance with tumor status in patients with metastatic lung cancer. The clinical data will be presented in a poster presentation at the International Association of Lung Cancer’s 16th World Conference on Lung Cancer in Denver on September 8, 2015.

“Results of our study indicate that the non-invasive Target Selector™ assay could have a role in managing patients with metastatic lung cancer”

“Results of our study indicate that the non-invasive Target Selector™ assay could have a role in managing patients with metastatic lung cancer,” said Lyudmila A. Bazhenova, M.D., UC San Diego Moores Cancer Center. “For example, a patient was correctly identified as having an emerging T790M resistance to Tyrosine Kinase Inhibitors (TKI) with the Target Selector™ assay prior to confirmation by tissue biopsy. This patient was then placed on a next-generation tyrosine kinase inhibitor and has subsequently demonstrated radiographic response to this change in treatment.”

“These study data further build on clinical evidence that the Target Selector™ affords non-invasive profiling of a tumor’s genomic landscape by monitoring treatment response and early detection of the emergence of resistance,” said Veena Singh, MD, Biocept’s Senior Vice President and Senior Medical Director. “The high concordance and level of specificity and sensitivity of the Target Selector™ assay shown in this study suggest that it has utility in the re-stratification of patients due to tumoral heterogeneity in order to qualify them for TKI therapy.

“Further, the Target Selector™ is performed on a simple blood sample which is also known as a liquid biopsy. Liquid biopsies are used when the initial diagnostic tissue biopsy sample is depleted, which can occur as much as 20% of the time. These patients are often too sick for additional invasive tissue sampling or refuse another surgical procedure. In addition, our liquid biopsy tests provide cost savings when compared with surgical tissue biopsies, thus delivering an added economic benefit to the healthcare system in general,” added Dr. Singh.

About the World Conference on Lung Cancer

The World Conference on Lung Cancer is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses, allied health professionals, advocates and patients.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers biomarker assays for lung, breast, colorectal and gastric Cancers, as well as melanoma. The company plans to introduce CLIA-validated assays for prostate and other solid tumors in the near term.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the role of our assay in managing patients with metastatic lung cancer, our ability to validate the use of liquid biopsies for targeted therapies, the ability to identify indicators of resistance to therapy, improvement of outcomes, our impact on diagnostic strategies and healthcare costs and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Contacts

Investors:
LHA
Jody Cain, 310-691-7100
jcain@lhai.com

Release Tags

Biocept, Inc.